The 2023 ART guideline introduces simplified ART provision and harmonised methods of management of children, adolescents and adults,
as well as pregnant women living with HIV/AIDS, TB and other common opportunistic infections.
The guidelines also provide guidance on the use of Dolutegravir (DTG) dispersible tablets for children from 3kg and 4 weeks old.
These guidelines have been revised with the Differentiated Models of Care SOPs to ensure simultaneous consideration and alignment of clinical,
adherence and service delivery updates.
The Differentiated Models of Care SOPs form part of this guidance to enable optimal use of decentralised and integrated service delivery
to promote a patient-centred approach. Effective implementation of these guidelines will increase access to ART services, advance South Africa’s
ability to control the epidemic and help to achieve the 2030 SDG goals.